Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4

Conditions

Sarcoma, Kaposi 4Neoplasms 4HIV Infections 4Acquired Immunodeficiency Syndrome 4

Interventions

Doxorubicin 10Zidovudine 9Vincristine 7Bleomycin 7Nivolumab 6Liposomes 5Interferon alpha-2 5Etoposide 5tecogalan 4pembrolizumab 4liposomal doxorubicin 4Valganciclovir 4Specimen Handling 4Semaxinib 4Paclitaxel 4Nelfinavir 4Magnetic Resonance Spectroscopy 4pomalidomide 3Ritonavir 3Filgrastim 3Biopsy 3Bevacizumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2sargramostim 2interferon alfa-n1 2Propranolol 2Indinavir 2Docetaxel 2Didanosine 2Daunorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Sarcoma, Kaposi × tecogalan × Clear all
NCT00002136 2005-06-24

A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002137 2005-06-24

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002138 2005-06-24

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002342 2005-06-24

A Study of Tecogalan Sodium

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡